The Most Common Claims That Trigger D&O Insurance

This is the allegation that appears in more D&O claims than any other. Directors and officers owe legal duties to the company and its stakeholders — primarily the duty of care (making decisions with adequate information and diligence) and the duty of loyalty (acting in the company's interest, not their own). When either duty is alleged to have been violated, a D&O claim follows.

Common scenarios include:

• A board approving an acquisition without adequate due diligence
• An executive steering a contract to a vendor in which they hold a personal financial interest
• Directors failing to act on known compliance failures that later resulted in shareholder losses
• A CEO prioritizing a transaction that benefits major shareholders at the expense of minority investors

Fiduciary duty claims are particularly common in M&A contexts. When a company is sold, dissatisfied shareholders routinely allege that the board accepted an inadequate price, failed to run a proper sales process, or had conflicts of interest that tainted the deal. These so-called Revlon claims (named after the landmark Delaware case) have become almost reflexive in larger transactions.

The business judgment rule provides directors with significant protection — courts generally won't second-guess a business decision made in good faith, with adequate information, and in the honest belief it served the company's interests. But that protection only holds if the process was genuinely sound. D&O defense counsel spends enormous effort reconstructing the decision-making process precisely because that process determines whether the rule applies.

Executives communicate constantly — in earnings calls, investor presentations, SEC filings, offering memoranda, and press releases. Every one of those communications is a potential source of a misrepresentation claim if the stated facts later prove incorrect or if material information was omitted.

Securities fraud claims under Rule 10b-5 are the highest-profile version of this exposure, typically brought as shareholder class actions when a company's stock drops sharply after a disclosure corrects earlier optimistic statements. But misrepresentation claims are not limited to public companies. Private company directors face them in:

• Investor relations — claiming a startup's technology was further along than it was
• Credit facility negotiations — providing inflated financial projections to lenders
• M&A transactions — representations and warranties in purchase agreements that later prove false
• Customer or partner agreements — overstating product capabilities in material ways

The Side C coverage component of a D&O policy — entity securities coverage — is specifically designed to respond to securities claims against the company itself. But individual directors and officers face personal exposure under Side A when they are named defendants. Underwriters scrutinize disclosure practices carefully during the underwriting process, and companies with a history of guidance misses or restatements will pay for it at renewal.

Many business owners conflate Employment Practices Liability Insurance (EPLI) with D&O coverage. They are distinct products, but there is meaningful overlap when an employee names an individual executive — rather than just the company — as a defendant in a discrimination, harassment, wrongful termination, or retaliation claim.

When an employee alleges that a specific officer made the decision to fire them in retaliation for raising a compliance concern, or that a director created or enabled a hostile work environment, that officer or director faces personal liability. The company's EPLI policy may cover the entity, but the individual's defense costs and exposure often fall to D&O Side A coverage — particularly if the company cannot indemnify the individual (due to insolvency, legal prohibition, or conflict of interest).

This exposure is significantly underappreciated by executives at private companies and nonprofits. See Why D&O Claims Often Arise From Inside the Company for a detailed look at how employees, co-directors, and shareholders become plaintiffs — often simultaneously.

Whistleblower retaliation claims deserve specific mention. Following the Sarbanes-Oxley Act and Dodd-Frank amendments, federal whistleblower protections are robust, and retaliation claims carry significant statutory damage exposure. An officer who fires an employee shortly after that employee raises an accounting concern is in genuinely dangerous territory, regardless of whether other legitimate performance reasons existed.

A formal lawsuit is not required to trigger D&O coverage. Most well-drafted policies respond to formal investigations — including SEC inquiries, DOJ criminal investigations, state attorney general enforcement actions, and regulatory proceedings from bodies like the FDIC, FTC, or CFPB. The moment a government agency issues a formal order of investigation naming an individual director or officer, defense coverage should activate.

This matters enormously in practice. Regulatory investigations can run for years before any formal charges are filed — or may never result in charges at all. The defense costs accumulated during that investigative period can be staggering. Legal counsel experienced in regulatory matters doesn't come cheap, and executives under investigation typically need representation from the moment they receive a document subpoena.

The coverage mechanics here are nuanced. Regulatory Investigations and D&O Coverage explains exactly how SEC inquiries, DOJ investigations, and agency enforcement actions interact with policy terms. Key issues include:

• Whether the investigation trigger language in your policy requires a formal order versus a written inquiry
• How the policy handles situations where the company and an individual officer have conflicting interests in an SEC investigation
• Whether civil money penalties and disgorgement are covered (usually not, due to public policy exclusions) versus defense costs (usually yes)

Financial services firms, healthcare companies, and technology businesses with significant data practices face elevated regulatory investigation exposure and should ensure their D&O tower adequately addresses this specific risk.

When a company becomes insolvent, the fiduciary duties of directors shift — in many jurisdictions, they expand to include the interests of creditors, not just shareholders. This creates a distinct class of D&O claimant that most executives don't anticipate until it's directly relevant to them: lenders, bondholders, trade creditors, and bankruptcy trustees pursuing directors and officers for decisions made in the period leading up to the insolvency filing.

Common creditor allegations in insolvency-related D&O claims include:

• Deepening insolvency — alleging that directors continued to operate and incur debt after the company was already insolvent, worsening the position of creditors
• Fraudulent conveyance — alleging that the board approved transactions that transferred assets at below-market value in ways that harmed creditors
• Preference payments — alleging that officers directed payments to favored creditors shortly before bankruptcy in violation of the automatic stay or preference rules

The complication in insolvency scenarios is the insured vs. insured exclusion — a standard D&O policy exclusion that bars coverage for claims brought by one insured against another. When a bankruptcy trustee (who steps into the company's shoes) sues former directors, some insurers argue the exclusion applies. This is actively litigated territory, and how your policy drafts the insured vs. insured exclusion — specifically whether it carves out bankruptcy trustees — is material. Review that language carefully at renewal.

Boards are not expected to manage companies — that's management's job. But boards are expected to establish and maintain adequate oversight systems, monitor compliance, and ensure that internal controls are functioning. When they fail to do so, and that failure contributes to corporate harm, the claim is typically framed as a failure of oversight — sometimes called a Caremark claim, after the landmark Delaware case that defined directors' duty to monitor.

Caremark-type claims were historically difficult for plaintiffs to win because courts set a high bar: plaintiffs must show that directors utterly failed to implement a reporting system, or consciously disregarded red flags once a reporting system was in place. But recent Delaware decisions have lowered that bar meaningfully in cases involving mission-critical compliance failures — particularly in heavily regulated industries like banking, pharmaceuticals, and food safety.

Practical examples of Caremark-adjacent D&O triggers:

• A board that received repeated audit committee warnings about cybersecurity vulnerabilities and failed to act — followed by a major breach and resulting data theft. (Note that cyber liability coverage under a separate policy may also respond; see Cyber Liability coverage for how that interacts with D&O.)
• Directors who ignored internal whistleblower complaints about financial reporting irregularities that later resulted in a restatement
• An executive team that failed to implement any anti-corruption compliance program despite operating in high-risk international markets

The lesson for boards is straightforward: document your oversight activity. Board minutes, audit committee reports, management presentations received, and responses to flagged issues all become critical evidence when a Caremark claim is brought.

Distinct from fiduciary duty breaches (which focus on decision-making process), mismanagement claims focus on the outcome of operational decisions that resulted in demonstrable financial harm to the company. These claims allege that an officer or director made business decisions so obviously imprudent that they cannot be protected by the business judgment rule.

This claim type is particularly common in:

• Nonprofit boards — where directors who approve excessive executive compensation, fail to monitor grant expenditures, or ignore financial irregularities face personal exposure from state attorneys general and disgruntled donors
• Private equity-backed companies — where sponsor-appointed directors may face claims that they extracted value through management fees or related-party transactions at the expense of the portfolio company
• Family businesses transitioning to professional management — where founder-directors may face claims from new institutional investors or minority shareholders alleging that historic management decisions were self-interested

The line between legitimate business risk-taking and actionable mismanagement is not always obvious. Courts apply the business judgment rule generously, but that protection evaporates quickly when a plaintiff can show the director was uninformed, conflicted, or acting in bad faith. The defense costs alone in a sustained mismanagement claim — even one that ultimately fails — can run into the millions. That's precisely why D&O coverage matters even for executives who are confident they've done nothing wrong.